An update on new and emerging options for the treatment of vitiligo

Vitiligo is an acquired leukoderma that results from the loss of epidermal melanocytes, and is characterized by macules and patches of depigmented skin. With a relatively high rate of prevalence, vitiligo occurs in localized, generalized, or segmental patterns; it can run a rapidly progressive cours...

Full description

Saved in:
Bibliographic Details
Published in:Skin therapy letter 2008-03, Vol.13 (2), p.1-6
Main Authors: Mahmoud, B H, Hexsel, C L, Hamzavi, I H
Format: Article
Language:English
Subjects:
Administration, Cutaneous
Adrenal Cortex Hormones - therapeutic use
Calcitriol - analogs & derivatives
Calcitriol - therapeutic use
Combined Modality Therapy
Dermatologic Agents - therapeutic use
Humans
Immunosuppressive Agents - therapeutic use
Low-Level Light Therapy
Phototherapy
Tacrolimus - therapeutic use
Vitiligo - drug therapy
Vitiligo - radiotherapy
Vitiligo - surgery
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Vitiligo is an acquired leukoderma that results from the loss of epidermal melanocytes, and is characterized by macules and patches of depigmented skin. With a relatively high rate of prevalence, vitiligo occurs in localized, generalized, or segmental patterns; it can run a rapidly progressive course or remain stationary. The pathogenesis of vitiligo is not yet fully understood, but the autoimmune hypothesis is the most commonly accepted one, based on which, many treatment modalities have been described. Although many therapeutic options exist and new modalities are still emerging, treatment challenges persist, as not all patients respond to available therapies. Variables that affect the choice of treatment include the extent, distribution, and progression rate of the lesions. Another challenge is the lack of a standardized scoring system, which hampers the production of level 1a evidence studies for the treatment of this condition.
ISSN:1201-5989